Gyre Therapeutics is buying Cullgen in an all‑stock deal valued at approximately $300 million, aiming to close in the second quarter of 2026, while advancing a conditional approval filing in China for hydronidone in chronic hepatitis B (CHB)–associated liver fibrosis with priority review eligibility. The company reported 2025 revenue of $116.6 million, up 10% year over year, but guided 2026 revenue down to $100.5–$111.0 million as it pivots resources toward regulatory milestones. Gyre also completed enrollment in a 52‑week Phase 3 trial of pirfenidone in pneumoconiosis and plans a 2026 U.S. IND for hydronidone in MASH‑associated liver fibrosis.
The strategic question is whether Gyre can convert a China-first fibrosis franchise into a diversified, cross‑border growth engine. Absorbing Cullgen’s targeted protein degradation and degrader antibody conjugate capabilities shifts Gyre from a single‑pillar fibrosis story to a broader modality portfolio spanning inflammation and oncology, with discovery footing in the U.S. The timing is deliberate: pairing a near‑term regulatory catalyst in China with a higher‑risk, platform‑level bet is an attempt to balance cash generation and innovation, while mitigating China policy exposure and creating optionality for Western partnerships.
For patients and hepatology leaders in China, hydronidone’s conditional filing matters now. CHB remains a substantial driver of liver fibrosis and cirrhosis, and the Phase 3 program reported fibrosis regression at 52 weeks. A priority review pathway could accelerate availability, but payer acceptance will hinge on endpoint durability, confirmatory commitments, and the speed of National Reimbursement Drug List negotiations. For Medical Affairs, this is a textbook case for early RWE planning: bridging histologic gains to outcomes that resonate with payers and provincial procurement bodies will be essential to maintain price integrity post‑launch.
Commercially, Gyre’s portfolio still leans on Etuary (pirfenidone), which delivered $106.1 million in 2025 sales, while newer products Etorel (nintedanib) and Contiva (avatrombopag) contributed $4.6 million and $5.5 million, respectively. The 2026 guide down reflects a self‑declared transition year and caution around China’s centralized procurement mechanics, which continue to compress margins and rewire brand tactics across respiratory and specialty categories. Expect moderated promotion and a heavier tilt toward regulatory and evidence‑generation workstreams. For competitors in anti‑fibrotics, the mix of legacy brands under tender pressure and a potentially new liver fibrosis entrant will test formulary strategies and guideline influence.
The Cullgen combination aligns with a broader industry pattern: platform‑rich biotechs seeking scale through M&A as targeted protein degradation matures from concept to clinic. For Business Development teams, the tie‑up creates a two‑speed asset base—near‑term China catalysts to anchor valuation, plus modality breadth to seed partnering in oncology and immunology. For Medical Affairs, it expands stakeholder maps beyond pulmonology and hepatology into tumor‑specific networks, raising the bar on biomarker strategy and trial site activation across geographies.
Three watch points will determine whether Gyre’s recalibration pays off: formal acceptance and review pace for hydronidone’s China filing and the contours of any post‑marketing confirmatory plan; the design and execution of the 2026 U.S. IND path in MASH‑associated fibrosis amid evolving regulatory expectations and endpoint scrutiny; and the integration cadence for Cullgen, particularly how quickly the combined entity can translate degrader programs into value‑creating milestones. Can Gyre turn a China regulatory win and a modality acquisition into a defensible, globally credible growth arc before procurement headwinds and clinical risk dilute momentum?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
